why choose us

First received: October 11, 2022

Clinical Trial: Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

Study Status: Completed

Recruit Status: RECRUITING

Condition: Allogeneic Stem Cell Transplantation

Study Type: INTERVENTIONAL


Official Title: Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant: a Randomized, Multicenter, Double-blind , Placebo-controlled Study Evaluating Twice Daily Oral Xylitol

Brief Summary: Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT).Unfortunately, there are currently no known strategies to prevent these BSI in this vulnerable population.The investigators will conduct a randomized, double-blind, placebo-controlled trial at three institutions to evaluate the effectiveness of twice daily intraoral xylitol-wipe application on reducing BSI in pediatric SCT…

Read more